Nkarta, Inc. (NASDAQ:NKTX) shares saw unusually-high trading volume on Thursday . Approximately 11,983 shares were traded during trading, a decline of 95% from the previous session’s volume of 233,713 shares.The stock last traded at $25.13 and had previously closed at $25.42.
Several analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Nkarta in a research report on Wednesday, March 17th. Evercore ISI reaffirmed a “buy” rating and set a $70.00 price target on shares of Nkarta in a research note on Sunday, May 9th. Finally, Zacks Investment Research cut shares of Nkarta from a “hold” rating to a “sell” rating in a research report on Tuesday, April 27th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $64.00.
The business’s 50 day moving average is $31.87 and its 200-day moving average is $43.81.
In other Nkarta news, CEO Paul J. Hastings sold 17,000 shares of the stock in a transaction on Tuesday, March 30th. The shares were sold at an average price of $30.74, for a total transaction of $522,580.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Nadir Mahmood sold 3,000 shares of the firm’s stock in a transaction dated Monday, May 10th. The stock was sold at an average price of $27.16, for a total transaction of $81,480.00. The disclosure for this sale can be found here. Insiders sold 23,500 shares of company stock valued at $718,510 over the last quarter.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its holdings in shares of Nkarta by 36.4% during the fourth quarter. BlackRock Inc. now owns 1,804,723 shares of the company’s stock valued at $110,936,000 after purchasing an additional 481,337 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Nkarta by 3,218.2% during the 1st quarter. JPMorgan Chase & Co. now owns 242,162 shares of the company’s stock valued at $7,967,000 after purchasing an additional 234,864 shares during the period. Sectoral Asset Management Inc bought a new position in Nkarta during the 1st quarter worth $5,562,000. Caas Capital Management LP acquired a new stake in Nkarta in the fourth quarter worth $10,014,000. Finally, Wasatch Advisors Inc. lifted its stake in Nkarta by 21.8% in the first quarter. Wasatch Advisors Inc. now owns 519,218 shares of the company’s stock valued at $17,082,000 after buying an additional 92,762 shares during the last quarter. Hedge funds and other institutional investors own 77.12% of the company’s stock.
Nkarta Company Profile (NASDAQ:NKTX)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Featured Article: Commodities
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.